|
1
|
Moss EL, Hollingworth J and Reynolds TM:
The role of CA125 in clinical practice. J Clin Pathol. 58:308–312.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lakhani SR, Manek S, Penault-Llorca F, et
al: Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin
Cancer Res. 10:2473–2481. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rafnar T, Gudbjartsson DF, Sulem P, et al:
Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet.
43:1104–1107. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ducros E, Mirshahi S, Azzazene D, et al:
Endothelial protein C receptor expressed by ovarian cancer cells as
a possible biomarker of cancer onset. Int J Oncol. 41:433–440.
2012.PubMed/NCBI
|
|
5
|
Fung FK, Chan DW, Liu VW, Leung TH, Cheung
AN and Ngan HY: Increased expression of PITX2 transcription factor
contributes to ovarian cancer progression. PLoS One. 7:e370762012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ishibashi M, Nakayama K, Yeasmin S, et al:
A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a
potential target for taxol resistance in ovarian cancer. Clin
Cancer Res. 14:3149–3155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rajkumar T, Soumittra N, Nancy NK,
Swaminathan R, Sridevi V and Shanta V: BRCA1, BRCA2 and CHEK2 (1100
del C) germline mutations in hereditary breast and ovarian cancer
families in south india. Asian Pac J Cancer Prev. 4:203–208.
2003.PubMed/NCBI
|
|
8
|
Ghadersohi A, Odunsi K, Zhang S, et al:
Prostate-derived Ets transcription factor as a favorable prognostic
marker in ovarian cancer patients. Int J Cancer. 123:1376–1384.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tassi RA, Calza S, Ravaggi A, et al:
Mammaglobin B is an independent prognostic marker in epithelial
ovarian cancer and its expression is associated with reduced risk
of disease recurrence. BMC Cancer. 9:2532009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rahman M, Nakayama K, Rahman M, et al:
Fatty acid synthase expression associated with NAC1 is a potential
therapeutic target in ovarian clear cell carcinomas. Brit J Cancer.
107:300–307. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ng CK, Cooke SL, Howe K, et al: The role
of tandem duplicator phenotype in tumour evolution in high-grade
serous ovarian cancer. J Pathol. 226:703–712. 2012. View Article : Google Scholar
|
|
12
|
Ahmed AA, Mills AD, Ibrahim AE, et al: The
extracellular matrix protein TGFBI induces microtubule
stabilization and sensitizes ovarian cancers to paclitaxel. Cancer
Cell. 12:514–527. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krueger F, Kreck B, Franke A and Andrews
SR: DNA methylome analysis using short bisulfite sequencing data.
Nat Methods. 9:145–151. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Madougou S, Santcroos M, Benabdelkader A,
et al: Provenance for distributed biomedical workflow execution.
Stud Health Technol Inform. 175:91–100. 2012.PubMed/NCBI
|
|
15
|
Mao X, Cai T, Olyarchuk JG and Wei L:
Automated genome annotation and pathway identification using the
KEGG orthology (KO) as a controlled vocabulary. Bioinformatics.
21:3787–3793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Langmead B, Trapnell C, Pop M and Salzberg
SL: Ultrafast and memory-efficient alignment of short DNA sequences
to the human genome. Genome Biol. 10:R252009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mortazavi A, Williams BA, Mccue K,
Schaeffer L and Wold B: Mapping and quantifying mammalian
transcriptomes by RNA-seq. Nat Methods. 5:621–628. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Audic S and Claverie JM: The significance
of digital gene expression profiles. Genome Res. 7:986–995.
1997.PubMed/NCBI
|
|
19
|
Benjamini Y and Yekutieli D: The control
of the false discovery rate in multiple testing under dependency.
Ann Stat. 29:1165–1188. 2001.
|
|
20
|
Harr B and Schlötterer C: Comparison of
algorithms for the analysis of affymetrix microarray data as
evaluated by co-expression of genes in known operons. Nucleic Acids
Res. 34:e82006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Adamidi C, Wang Y, Gruen D, et al: De novo
assembly and validation of planaria transcriptome by massive
parallel sequencing and shotgun proteomics. Genome Res.
21:1193–1200. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Virtakoivu R, Pellinen T, Rantala JK,
Perälä M and Ivaska J: Distinct roles of AKT isoforms in regulating
β1-integrin activity, migration and invasion in prostate cancer.
Mol Biol Cell. 23:3357–3369. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dobashi Y, Kimura M, Matsubara H, Endo S,
Inazawa J and Ooi A: Molecular alterations in AKT and its protein
activation in human lung carcinomas. Hum Pathol. 43:2229–2240.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bellacosa A, De Feo D, Godwin AK, et al:
Molecular alterations of the AKT2 oncogene in ovarian and breast
carcinomas. Int J Cancer. 64:280–285. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Altomare DA, Wang HQ, Skele KL, et al: AKT
and mTOR phosphorylation is frequently detected in ovarian cancer
and can be targeted to disrupt ovarian tumor cell growth. Oncogene.
23:5853–5857. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chu CM: Natural history of chronic
hepatitis B virus infection in adults with emphasis on the
occurrence of cirrhosis and hepatocellular carcinoma. J Gastroen
Hepatol. 15:E25–E30. 2000. View Article : Google Scholar
|
|
27
|
Parsonnet J, Friedman GD, Vandersteen DP,
et al: Helicobacter pylori infection and the risk of gastric
carcinoma. N Engl J Med. 325:1127–1131. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sobhani I, Walker F, Roudot-Thoraval F, et
al: Anal carcinoma: incidence and effect of cumulative infections.
Aids. 18:1561–1569. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dreesen O and Brivanlou AH: Signaling
pathways in cancer and embryonic stem cells. Stem Cell Rev. 3:7–17.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Osman I, Drobnjak M, Fazzari M, et al:
Inactivation of the p53 pathway in prostate cancer: impact on tumor
progression. Clin Cancer Res. 5:2082–2088. 1999.PubMed/NCBI
|
|
31
|
Puzio-Kuter AM, Castillo-Martin M, Kinkade
CW, et al: Inactivation of p53 and Pten promotes invasive bladder
cancer. Genes Dev. 23:675–680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ho SM: Estrogen, progesterone and
epithelial ovarian cancer. Reprod Biol Endocrinol. 1:732003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pópulo H, Lopes JM and Soares P: The mTOR
signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guerrero K, Wang Z, Bachvarova M, et al: A
novel genome-based approach correlates TMPRSS3 overexpression in
ovarian cancer with DNA hypomethylation. Gynecol Oncol.
125:720–726. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Byrne J, Maleki S, Hardy JR, et al: MAL2
and tumor protein D52 (TPD52) are frequently overexpressed in
ovarian carcinoma, but differentially associated with histological
subtype and patient outcome. BMC cancer. 10:4972010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guo Y, Fu P, Zhu H, et al: Correlations
among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene
signatures of histological subtypes of patients with epithelial
ovarian cancer. Oncol Rep. 27:286–292. 2012.
|
|
37
|
Hwang JR, Jo K, Lee Y, Sung BJ, Park YW
and Lee JH: Upregulation of CD9 in ovarian cancer is related to the
induction of TNF-α gene expression and constitutive NF-κB
activation. Carcinogenesis. 33:77–83. 2012. View Article : Google Scholar
|
|
38
|
Seiz L, Dorn J, Kotzsch M, et al: Stromal
cell-associated expression of kallikrein-related peptidase 6 (KLK6)
indicates poor prognosis of ovarian cancer patients. Biol Chem.
393:391–401. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bock AJ, Nymoen DA, Brenne K, Kærn J and
Davidson B: SCARA3 mRNA is overexpressed in ovarian carcinoma
compared with breast carcinoma effusions. Hum Pathol. 43:669–674.
2012. View Article : Google Scholar
|
|
40
|
Chuan Y, Pang ST, Bergh A, Norstedt G and
Pousette A: Androgens induce CD-9 in human prostate tissue. Int J
Androl. 28:291–296. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cook GA, Wilkinson DA, Crossno JT Jr,
Raghow R and Jennings LK: The tetraspanin CD9 influences the
adhesion, spreading and pericellular fibronectin matrix assembly of
chinese hamster ovary cells on human plasma fibronectin. Exp Cell
Res. 251:356–371. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Furuya M, Kato H, Nishimura N, et al:
Down-regulation of CD9 in human ovarian carcinoma cell might
contribute to peritoneal dissemination: morphologic alteration and
reduced expression of β1 integrin subsets. Cancer Res.
65:2617–2625. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Notaridou M, Quaye L, Dafou D, et al:
Common alleles in candidate susceptibility genes associated with
risk and development of epithelial ovarian cancer. Int J Cancer.
128:2063–2074. 2011. View Article : Google Scholar :
|
|
44
|
Acampora D, D’esposito M, Faiella A, et
al: The human hox gene family. Nucleic Acids Res. 17:10385–10402.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ota T, Klausen C, Salamanca MC, Woo HL,
Leung PC and Auersperg N: Expression and function of HOXA genes in
normal and neoplastic ovarian epithelial cells. Differentiation.
77:162–171. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gendronneau G, Boucherat O, Aubin J,
Lemieux M and Jeannotte L: The loss of Hoxa5 function causes
estrous acyclicity and ovarian epithelial inclusion cysts.
Endocrinology. 153:1484–1497. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Morgan R, Plowright L, Harrington KJ,
Michael A and Pandha HS: Targeting HOX and PBX transcription
factors in ovarian cancer. BMC cancer. 10:892010. View Article : Google Scholar : PubMed/NCBI
|
